Delving into the Latest Updates on Siegfried Irvine with Synapse

Overview

Tags

Eye Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

Prostanoid receptor	1

Primary objective: To evaluate the pharmacokinetic characteristics of single and multiple administrations of 0.1% NCX 470 eye drops in healthy Chinese subjects Secondary objective: To evaluate the safety and tolerability of single and multiple administrations of 0.1% NCX 470 eye drops in healthy Chinese subjects

Start Date22 Feb 2023

Sponsor / Collaborator

Nicox Ophthalmics, Inc.

[+2]

100 Clinical Results associated with Siegfried Irvine

Login to view more data

0 Patents (Medical) associated with Siegfried Irvine

Login to view more data

100 Deals associated with Siegfried Irvine

Login to view more data

100 Translational Medicine associated with Siegfried Irvine

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data